Inter-group comparisons revealed that the dominant CD8+ TCR-Vβ+ expansions in T-LGLL patients expressed significantly higher levels of CD57 and 2B4 and significantly lower levels of CD27 and CD127 compared with the dominant CD8+ TCR-Vβ+ expansions in dasatinib-treated CML patients (Fig. 3B, top panel). The gene discussed is CD8A; the disease is T-cell large granular lymphocyte leukemia.